**Supplementary Table 2**

**Factors associated with non-regression of liver fibrosis stage after direct-acting antiviral agent therapy between end of treatment and SVR24**

|  |  |  |  |
| --- | --- | --- | --- |
| At EOT | **Regression** | **Non-regression** | **P value** |
| **Number** | **14** | **10** |  |
| Age (years)a | 60(33-75) | 67(44-81) | 0.212 |
| Sex (male/female) | 5/9 | 3/7 | 0.561 |
| HCV-RNA (log IU/mL) a | 0 | 0 |  |
| DCV/ASV,　SOF/LDV,　 SOF/RBV, 　OBV/PTV/r | 4/6/3/1 | 1/3/6/0 | 0.236 |
| F0-2/3-4 | 12/2 | 5/5 | 0.075 |
| Platelet count (×104) a | 18.5(13.2-28) | 16.6(4.8-20.3) | 0.064 |
| AST (IU/L) a | 21(11-35) | 25(21-74) | \*0.026 |
| ALT (IU/L) a | 16(6-30) | 19(5-71) | 0.546 |
| FIB-4 index a | 1.73(0.72-4.56) | 3.58(1.67-9.72) | \*0.009 |
| Angiopoietin-2 (pg/mL) a | 211.6(139.8-543.8) | 345.6(205.8-913) | \*0.019 |
| CAP (dB/m) a | 218(123-270) | 197(100-386) | 0.625 |
| Spleen index (cm2) a | 25.9(13-56.5) | 30.7(18-49.5) | 0.135 |

Abbreviations: HCV, Hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FIB-4, fibrosis 4; CAP, Controlled Attenuation Parameter.

a Data are shown as median (range) values. \*Statistically significant difference, P <0.05.